drugset
drugset / Trial / NCT00257010

A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches

NCT00257010 ↗

Phase 3 Completed 447 enrolled Janssen-Ortho LLC Ortho-McNeil Neurologics, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety of almotriptan malate (a migraine headache medication) in the treatment of migraine headaches in adolescents for up to one year.

Timeline

Start
2005-12
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject almotriptan Small molecule 12.5 mg Oral

Indications

migraine disorder